Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02815891 · ClinicalTrials.gov registry record
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
A clinical trial of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver, sponsored by Target PharmaSolutions.
- Recruiting
- Registry status
- 15,000
- Enrollment target
- 20
- Study locations
NCT02815891 is a study of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver that is actively recruiting participants, run by Target PharmaSolutions. The registered enrollment target is 15,000 participants, above the 148-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (10035% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT02815891, a study of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver, is actively recruiting participants, sponsored by Target PharmaSolutions.
- RECRUITING
- Registry status
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Conditions Studied
Study Locations (20)
Florida
- Gastro Florida - Clearwater
- University of Florida Hepatology Research at CTRB - Gainesville
- University of Florida - Gainesville
- UF Health Gastroenterology - Jacksonville
- University of Miami - Miami
- Schiff Center for Liver Disease/University of Miami - Miami
- AdventHealth Diabetes Institute - Orlando
- Advanced Gastroenterology Associates, LLC - Palm Harbor
- Tampa General Medical Group - Tampa
California
- Stanford University - Palo Alto
- California Liver Research Institute - Pasadena
- University of California, Davis - Sacramento
- Silicon Valley Research Institute - San Jose
Connecticut
- Connecticut Gastroenterology - Hartford
- Connecticut Children's Medical Center - Hartford
Georgia
- Atlanta Gastroenterology Associates, LLC - Atlanta
- Emory University - Children's Healthcare of Atlanta - Atlanta
Arizona
- Banner University Medical Center - Phoenix Transplant Center and Advanced Liver Clinic - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
District of Columbia
- Medstar Georgetown Transplant Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2016-07 |
| Est. Completion | 2036-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02815891
The ClinicalTrials.gov registry entry for NCT02815891 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 148-participant average among 17 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (10035% higher). The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 0 interventions.
NCT02815891 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02815891 about?
NCT02815891 is a clinical study titled "A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)". TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintain...
What is the current status of trial NCT02815891?
This trial is currently recruiting. The enrollment target is 15,000 participants. The study started on 2016-07. Estimated completion is 2036-07.
What conditions does trial NCT02815891 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver.
Who is sponsoring clinical trial NCT02815891?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02815891 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Metabolic Pathology of Pediatric NAFLD
RECRUITING · NA
-
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
RECRUITING
-
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.